Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis

Autor: Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Norifumi Kawada, Masayuki Kurosaki, Akio Ido, Daiki Miki, Hitoshi Yoshiji, Yasuhiro Takikawa, Ryotaro Sakamori, Yoichi Hiasa, Kazuhiko Nakao, Naoya Kato, Yoshiyuki Ueno, Hiroshi Yatsuhashi, Yoshito Itoh, Ryosuke Tateishi, Goki Suda, Taro Takami, Yasunari Nakamoto, Yasuhiro Asahina, Kentaro Matsuura, Taro Yamashita, Tatsuya Kanto, Norio Akuta, Shuji Terai, Masahito Shimizu, Satoshi Sobue, Tomokatsu Miyaki, Akihiro Moriuchi, Ryoko Yamada, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara
Rok vydání: 2022
Předmět:
Zdroj: Journal of Gastroenterology. 57:120-132
ISSN: 1435-5922
0944-1174
Popis: Direct-acting antiviral (DAA) therapy enables a high rate of sustained virologic response (SVR) in patients with hepatitis C virus associated cirrhosis. However, the impact of DAA therapy on liver-related events in patients with cirrhosis is unclear.A total of 350 patients with compensated and decompensated cirrhosis administered DAA therapy at 29 Japanese hospitals were enrolled (Child-Pugh class A [CP-A]: 195 patients, CP-B: 131 patients and CP-C: 24 patients).The SVR rates of patients with CP-A, CP-B and CP-C were 96.9%, 93.1% and 83.3%, respectively (p = 0.006). Seventy patients developed hepatocellular carcinoma (HCC), and male sex, previous HCC treatment, platelet counts 10.0 × 10HCC development and mortality in patients with CP-B were not different from those with CP-A. On the other hand, in patients with CP-C, the development of HCC and decompensated cirrhotic events requiring hospital admission, and death were frequent.University Hospital Medical Information Network (UMIN000036150).
Databáze: OpenAIRE
Externí odkaz: